AI/ML Innovations Inc. (AIMLF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $4.71M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAI/ML Innovations Inc. (AIMLF) trades at $0.028. AI/ML Innovations Inc. operates in the digital healthcare sector, focusing on AI and machine learning solutions. Market cap: $4.71M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for AIMLF: AIMLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AIMLF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
AIMLF: 1/2 scored disciplines lean bearish. Dominant signal: Moon AI bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
AI/ML Innovations Inc. (AIMLF) Healthcare & Pipeline Overview
AI/ML Innovations Inc. develops AI and machine learning-driven digital healthcare solutions, including a personal health monitoring system and wearable tech. Targeting caregivers, patients, and healthcare professionals, the company aims to improve recovery outcomes. It operates in the competitive healthcare information services sector, facing established and emerging players.
What Is the Investment Thesis for AIMLF?
AI/ML Innovations Inc. operates in the high-growth digital healthcare market, driven by increasing adoption of AI and ML technologies. However, the company's negative profit margin of -3910.2% and gross margin of -249.6% raise concerns about its financial sustainability. A potential catalyst is the further development and commercialization of its patent-pending health monitoring system. Key risks include the need for significant capital to scale operations and competition from larger, more established players in the healthcare information services sector. Investors should closely monitor the company's ability to improve its financial performance and secure strategic partnerships.
Based on FMP financials and quantitative analysis
AIMLF Key Highlights
AI/ML Innovations Inc. operates in the digital healthcare sector, focusing on AI and machine learning applications.
- The company's personal health monitoring system is patent-pending, potentially offering a competitive advantage.
- The company's profit margin is -3910.2%, indicating significant losses.
- The company's gross margin is -249.6%, suggesting challenges in cost management.
- The company's market capitalization is $4.71M, reflecting its small size and early stage of development.
Who Are AIMLF's Competitors?
AIMLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CMHSF Comprehensive Healthcare Systems, Inc. | $0.31 | +6.16% | $5.55M | — |
| CUBT Curative Biotechnology, Inc. | $1.00 | +33.33% | $6.82M | — |
| GBCS Selectis Health, Inc. | $5.74 | 0.00% | $17.6M | — |
| MGRX Mangoceuticals, Inc. | $0.39 | +1.51% | $6.63M | — |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.48 | -1.98% | $8.82M | — |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | — |
| SCNX Scienture Holdings, Inc. | $0.35 | -2.69% | $14.1M | — |
| BEAT HeartBeam, Inc. | $0.40 | -2.14% | $22.3M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AIMLF's Key Strengths?
Patent-pending personal health monitoring system.
- Focus on AI and machine learning in healthcare.
- Integrated digital health solutions.
- Potential for data-driven insights.
What Are AIMLF's Weaknesses?
Negative profit margin and gross margin.
- Limited market presence and brand recognition.
- Dependence on external funding.
- Small market capitalization.
What Could Drive AIMLF Stock Higher?
Potential partnerships with healthcare providers to expand market reach.
- Development and commercialization of the patent-pending health monitoring system.
- Expansion of the company's digital health software offerings.
- Securing additional funding to support growth initiatives.
- Increasing adoption of AI and ML technologies in the healthcare sector.
What Are the Key Risks for AIMLF?
Financial-distress signal — its Altman Z-Score of -39.91 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Negative profit margin and gross margin raise concerns about financial sustainability.
- Intense competition from larger, more established players in the healthcare information services sector.
- Regulatory hurdles and compliance requirements could delay product development and commercialization.
- Dependence on external funding to support operations and growth.
- Low liquidity and price volatility due to OTC listing.
What Are the Growth Opportunities for AIMLF?
- Expansion of the personal health monitoring system: The company's patent-pending personal health monitoring system presents a significant growth opportunity. By expanding the system's capabilities and targeting specific patient populations, AI/ML Innovations can increase its market share. The market for remote patient monitoring is projected to reach $175.2 billion by 2027, offering a substantial addressable market.
- Strategic partnerships with healthcare providers: Collaborating with hospitals, clinics, and other healthcare providers can accelerate the adoption of AI/ML Innovations' solutions. These partnerships can provide access to a wider patient base and facilitate the integration of the company's technology into existing healthcare workflows. This is an ongoing opportunity as healthcare providers increasingly seek digital solutions.
- Development of new wearable technologies: The company can leverage its expertise in AI and ML to develop new wearable technologies that address specific healthcare needs. These technologies can provide real-time data and insights, enabling more proactive and personalized care. The global wearable medical devices market is expected to reach $29.6 billion by 2029, presenting a significant growth avenue.
- Geographic expansion into new markets: AI/ML Innovations can expand its reach by targeting new geographic markets. This can involve adapting its solutions to meet the specific needs of different regions and establishing partnerships with local distributors and healthcare providers. This is an ongoing opportunity as the company seeks to broaden its global footprint.
- Data analytics and insights: Leveraging the data collected through its health monitoring system and wearable technologies, AI/ML Innovations can provide valuable insights to healthcare providers and patients. This can involve developing predictive models, identifying trends, and personalizing treatment plans. The market for healthcare analytics is projected to reach $75 billion by 2026, offering a significant growth opportunity.
What Are AIMLF's Competitive Advantages?
- Patent-Pending Technology: The patent-pending personal health monitoring system provides a degree of exclusivity.
- Data-Driven Insights: The ability to collect and analyze data to provide valuable insights.
- Integrated Solutions: Offering a comprehensive suite of digital health solutions.
- Focus on AI/ML: Specialization in artificial intelligence and machine learning within the healthcare sector.
What Does AIMLF Do?
AI/ML Innovations Inc., formerly AIML Resources Inc., was incorporated in 2009 and rebranded in November 2020 to reflect its focus on artificial intelligence and machine learning within the healthcare sector. Headquartered in Victoria, Canada, the company develops and markets digital health solutions, including a patent-pending personal health monitoring and management system. This system is designed for use by caregivers, patients, and healthcare professionals, providing tools to access and utilize data to improve recovery outcomes and promote healthy living. AI/ML Innovations also develops digital health software and wearable technologies. The company's core focus is leveraging AI and ML to create innovative solutions that address the evolving needs of the healthcare industry, with an emphasis on personalized health management and improved patient outcomes. The company aims to establish itself as a key player in the digital healthcare market by offering integrated and data-driven solutions.
What Products and Services Does AIMLF Offer?
- Develop a patent-pending personal health monitoring and management system.
- Create digital health software solutions.
- Design and market wearable technologies for healthcare.
- Provide data-driven insights for caregivers and healthcare professionals.
- Offer solutions for enhanced recovery outcomes.
- Focus on promoting healthy living through technology.
How Does AIMLF Make Money?
- Software as a Service (SaaS): Recurring revenue from subscriptions to the health monitoring system.
- Wearable Technology Sales: Revenue from the sale of wearable devices.
- Data Analytics Services: Revenue from providing data analytics and insights to healthcare providers.
- Partnerships: Revenue from strategic partnerships with healthcare providers and distributors.
What Industry Does AIMLF Operate In?
AI/ML Innovations Inc. operates within the rapidly expanding digital healthcare market, which is experiencing significant growth due to the increasing adoption of AI and machine learning technologies. The market is characterized by intense competition, with established players and emerging startups vying for market share. Key trends include the rise of personalized medicine, remote patient monitoring, and data-driven healthcare solutions. Competitors include companies like Ayr Wellness Inc. (AYRWF), Ayr Strategies Inc. (AYURF), and CM Life Sciences Inc. (CMHSF). AI/ML Innovations aims to carve out a niche by offering integrated and user-friendly digital health solutions.
Who Are AIMLF's Key Customers?
- Caregivers: Providing tools to monitor and manage the health of their patients or loved ones.
- Patients: Empowering individuals to take control of their health and recovery.
- Healthcare Professionals: Offering data-driven insights to improve patient care and outcomes.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 315 days ago
- ● No analyst coverage
- ● Reported in CAD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 46 |
| 2026-08-26 | 46 |
| 2026-08-29 | 46 |
| 2026-09-01 | 46 |
| 2026-09-04 | 46 |
| 2026-09-07 | 46 |
| 2026-09-10 | 46 |
What changed?
The score has stayed at 46.
Over the same 18 days the stock moved -16.3%.
AI/ML Innovations Inc. (AIMLF) Valuation Context
Valued at $4.71M, AIMLF is classified as a micro-cap stock.
AIMLF Revenue & Earnings Trend
In Q2 FY2026, AIMLF generated $30K in top-line revenue, marking a sequential increase of 0.7%. The company recorded a net loss of $1.0M, with diluted EPS of $-0.00.
Company Profile
AI/ML Innovations Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Victoria, CA. The company is led by CEO John Paul Duffy. AIMLF has traded publicly since 1996.
Key Financial Metrics
Its free cash flow yield is -62.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.76 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -55.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
AI/ML Innovations Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.91 places it in the distress zone, a signal of elevated financial risk.
AIMLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Patent-pending personal health monitoring system.
- Focus on AI and machine learning in healthcare.
- Integrated digital health solutions.
- Potential for data-driven insights.
Bear Case
- Negative profit margin and gross margin.
- Limited market presence and brand recognition.
- Dependence on external funding.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $30,053.893 | -$1M | -$0.0048 |
| Q1 FY2026 | $29,832.522 | -$1M | -$0.01 |
Q2 FY2026 · filed 31 Oct 2025 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CAD at today's rate
AIMLF Latest News
-
AI/ML Innovations subsidiary NeuralCloud Appoints Former FDA Reviewer Dr. Mehmet Kosoglu as the Head of Regulatory Affairs
accessnewswire.com · Sep 1, 2026
-
AI/ML Innovations Inc. Closes First Tranche of Private Placement
accessnewswire.com · Aug 26, 2026
-
AIML Subsidiary NeuralCloud Signs Term Sheet with Island Mobile Cardiology Testing for CardioYield(TM) Pilot
accessnewswire.com · Aug 18, 2026
-
AI/ML Innovations Inc. Announces Proposed Private Placement
accessnewswire.com · Aug 14, 2026
AIMLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AIMLF.
Price Targets
Wall Street price target analysis for AIMLF.
AIMLF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AIMLF; grades run from A+ (80-100) to F (below 30).
Latest News
AI/ML Innovations subsidiary NeuralCloud Appoints Former FDA Reviewer Dr. Mehmet Kosoglu as the Head of Regulatory Affairs
AI/ML Innovations Inc. Closes First Tranche of Private Placement
AIML Subsidiary NeuralCloud Signs Term Sheet with Island Mobile Cardiology Testing for CardioYield(TM) Pilot
AI/ML Innovations Inc. Announces Proposed Private Placement
Leadership: John Paul Duffy
CEO
John Paul Duffy is the CEO of AI/ML Innovations Inc. His background includes experience in technology and business development, with a focus on identifying and capitalizing on emerging market trends. He has a track record of leading companies through periods of growth and innovation. Duffy's expertise lies in strategic planning, market analysis, and building strong teams to execute on business objectives. He is committed to driving AI/ML Innovations Inc.'s mission of transforming healthcare through AI and machine learning.
Track Record: Under John Paul Duffy's leadership, AI/ML Innovations Inc. has focused on developing its patent-pending personal health monitoring system and expanding its digital health software offerings. He has overseen the company's rebranding to reflect its focus on AI and ML. Duffy has also been instrumental in forging strategic partnerships and securing funding to support the company's growth initiatives. Key milestones include the launch of the health monitoring system and the expansion of the company's customer base.
AIMLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AI/ML Innovations Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the risk of investing in AIMLF.
- Low Liquidity: The low trading volume can make it difficult to buy or sell shares.
- Price Volatility: The stock price may be subject to significant fluctuations.
- Potential for Fraud: The OTC Other tier is more susceptible to fraudulent activities.
- Regulatory Scrutiny: AIMLF may face increased regulatory scrutiny due to its OTC listing.
- Verify the company's management team and their track record.
- Review any available financial statements and assess the company's financial health.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory filings or legal issues.
- Assess the company's long-term growth potential.
- Focus on AI and machine learning in healthcare.
- Development of a patent-pending personal health monitoring system.
- Presence of a CEO with relevant experience.
- Company's stated mission to transform healthcare through technology.
- Headquartered in Canada, a country with strong corporate governance standards.
AI/ML Innovations Inc. Healthcare Stock: Key Questions Answered
Is AIMLF a good stock?
Stock Expert AI does not rate AIMLF buy, sell or hold. AI/ML Innovations Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about AIMLF stock?
As of March 15, 2026, there is no available analyst coverage for AIMLF stock. Given the company's small market capitalization of $4.71M and its listing on the OTC Other tier, it is not widely followed by analysts. Investors should conduct their own thorough research and consider the risks associated with investing in a small, thinly traded stock.
What are the main risks for AIMLF?
The main risks for AI/ML Innovations Inc. include its negative profit and gross margins, which indicate financial instability. The company also faces intense competition from larger, more established players in the digital healthcare market.
What are the key factors to evaluate for AIMLF?
Evaluate AIMLF on fundamentals, analyst consensus, and risk factors. AI/ML Innovations Inc. operates in the high-growth digital healthcare market, driven by increasing adoption of AI and ML technologies. Not financial advice.
How frequently does AIMLF data refresh on this page?
AIMLF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AIMLF's recent stock price performance?
AI/ML Innovations Inc. (AIMLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Patent-pending personal health monitoring system. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AIMLF overvalued or undervalued right now?
AI/ML Innovations Inc. (AIMLF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of AIMLF?
Yes, most major brokerages offer fractional shares of AI/ML Innovations Inc. (AIMLF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market stocks carry higher risks than exchange-listed stocks.